PDB6 A Network Meta-Analysis (NMA) to Assess the Longer-Term Relative Efficacy of Canagliflozin in Patients with Type 2 Diabetes Inadequately Controlled on Metformin  by Taieb, V et al.
A598  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
PDB7
Bayesian network Meta-analysis (nMa) to assess the relative 
efficacy of canagliflozin in Patients with tyPe 2 DiaBetes Mellitus 
(t2DM) inaDequately controlleD with insulin
Taieb V1, Pacou M2, Schroeder M3, Nielsen AT4, Neslusan C5, Schubert A6
1Amaris, London, UK, 2Amaris, Paris, France, 3Janssen UK, High Wycombe, UK, 4Janssen-Cilag 
A/S, Birkerød, Denmark, 5Janssen Global Services, LLC, Raritan, NJ, USA, 6Janssen-Cilag Poland, 
Warsaw, Poland
Objectives: To assess the relative efficacy of canagliflozin, a sodium glucose co-
transporter 2 inhibitor (SGLT2) as add-on to insulin +/- oral antihyperglycaemic 
drugs for the treatment of T2DM compared to dipeptidyl peptidase-4 inhibitors 
(DPP-4s), glucagon-like peptide-1 receptor agonists (GLP-1s), sulphonylureas, piogl-
itazone, and other SGLT2 inhibitors, using Bayesian NMA methods. MethOds: 
A systematic literature review was conducted according to NICE guidelines and 
available data on HbA1c, weight and systolic blood pressure (SBP) were extracted. 
Networks were based on treatment- and dose-specific nodes, except for sulphonylu-
reas where doses were combined. Selection of fixed versus random effects was based 
on the deviance information criterion. Results were interpreted based on absolute 
differences and Bayesian probabilities for treatments to perform better than others 
(P), where P≤ 30% indicated a smaller effect and P≥ 70% a larger effect. Results: 
Eighteen trials reported results at 26 +/- 4 weeks. HbA1c reductions were highest 
for liraglutide 1.8mg, pioglitazone 45mg and glibenclamide. Canagliflozin 300mg 
had greater HbA1c reductions than all remaining comparators, except for exenatide 
where the reduction was similar. Canagliflozin 100mg had a greater reduction than 
dapagliflozin 5mg, vildagliptin, saxagliptin and lixisenatide and a similar reduction 
versus DPP-4s, glimepiride, lixisenatide, pioglitazone 30mg, metformin and dapa-
gliflozin 10mg. Both dosages of canagliflozin were associated with greater weight 
loss than DPP-4s, glibenclamide, pioglitazone 30mg and dapagliflozin (Δ = –2.13 to 
–3.45kg; Δ = –7.61 to –8.25kg; Δ = –3.34 to –3.95kg; Δ = –0.44 to –1.73kg, respectively). 
Weight reductions were highest for liraglutide 1.8mg and exenatide 10μ g. Both dos-
ages of canagliflozin had higher SBP reductions than dapagliflozin and saxagliptin; 
at least similar reductions were estimated versus exenatide 10μ g. cOnclusiOns: 
These results suggest that canagliflozin is a valuable treatment option as add-on 
to insulin therapy, as it provides not only similar or better glucose lowering than 
many other options, but also weight loss.
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Objectives: Improving glycaemic control is the primary goal of T2DM manage-
ment and can help to reduce the risk of micro- and macrovascular complications. 
Guidelines from the European Association for the Study of Diabetes (EASD) and 
the National Institute for Health and Care Excellence (NICE) recommend lower-
ing HbA1c to levels < 7.0% and < 7.5%, respectively. Canagliflozin, an agent that 
inhibits sodium glucose co-transporter 2, has been shown to reduce HbA1c, body 
weight, and blood pressure in a broad range of patients with T2DM. The objective 
of this study was to evaluate the proportions of T2DM patients achieving glycaemic 
targets with canagliflozin 100mg (CANA100) and canagliflozin 300mg (CANA300) 
versus placebo in triple therapy as add-on to metformin plus sulphonylurea 
(MET+SU). MethOds: Data were used from a 52-week Phase 3 study evaluating 
CANA100 and CANA300 versus placebo in T2DM patients on background MET+SU 
(N= 457; mean HbA1c, 8.1%). The proportions of patients with baseline HbA1c ≥ 7.0% 
or ≥ 7.5% who achieved HbA1c < 7.0% or < 7.5%, respectively, were assessed at weeks 
26 and 52. Patients with missing efficacy data were considered as non-responders. 
Odds ratios (ORs; [95% confidence interval]) by treatment were calculated using 
logistic regression. Results: Among patients with baseline HbA1c ≥ 7.0% (n= 425), a 
higher proportion achieved HbA1c < 7.0% with CANA100 (29.1%; OR= 2.65 [1.47;4.95]) 
and CANA300 (40.1%; OR= 4.34 [2.45;7.98]) versus placebo (13.4%; reference) at week 
52. Similarly, a higher proportion of patients with baseline HbA1c ≥ 7.5% (n= 330) 
achieved HbA1c < 7.5% with CANA100 (45.5%; OR= 4.13 [2.24;7.91]) and CANA300 
(54.1%; OR= 5.82 [3.15;11.15]) versus placebo (16.8%; reference) at week 52. Absolute 
response rates were higher at 26 weeks, but relative treatment effects were consist-
ent between 26 and 52 weeks. cOnclusiOns: Patients with T2DM treated with 
canagliflozin 100 and 300mg as add-on to MET+SU are more likely to achieve HbA1c 
targets of < 7.0% and < 7.5% compared to MET+SU only.
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Objectives: For people with Type 2 Diabetes Mellitus (T2DM) insufficiently con-
trolled with oral antidiabetic drugs (OADs), GLP-1 analogues proved to offer glycae-
mic control while mitigating the weight gain common with insulin. However, limited 
head-to-head evidence exists comparing daily GLP-1 analogues in this population. 
The aim of this study was to evaluate the relative efficacy and safety of liraglutide 
relative to other daily GLP-1 agonists for the treatment of people with T2DM not 
previously treated with insulin. MethOds: Following a systematic literature review, 
randomized controlled trials evaluating the following interventions in adults with 
T2DM were selected: liraglutide (1.2mg and 1.8mg), exenatide (5mcg and 10mcg 
BID), and lixisenatide (20mcg). Based on the available data we conducted network 
meta-analysis (NMA) for the following outcomes: Change from baseline HbA1c, 
proportion of patients meeting HbA1c target level, fasting plasma glucose (FPG), 
post-prandial glucose (PPG), systolic blood pressure (SBP), and weight, as well as 
rates of hypoglycemic events (severe and mild). Results: Liraglutide was found to 
conducted. Randomised controlled trials (RCTs) were of 24 weeks (± 6 weeks) treat-
ment duration. Bayesian fixed-effect (FE) and random-effects (RE) models were 
used to estimate the relative efficacy and tolerability, and 95% credible intervals 
(CrIs). Results: Fourteen RCTs were included. The RE model was selected a prio-
riover the FE model. The FE model did not provide a better fit to the data, based 
on the deviance information criterion. EQW was statistically significantly better 
than placebo (mean; 95% CrI) (-1.09%; -1.62% to -0.53%) in reducing HbA1c. EQW 
obtained a statistically significant reduction in HbA1c relative to lixisenatide 20ug 
QD. Favourable point estimates that did not reach statistical significance were 
observed for EQW vs. albiglutide 30mg QW, exenatide 5ug and 10ug twice daily 
(BID), and liraglutide 1.2mg and 1.8mg once daily (QD). A model adjusting for base-
line HbA1c did not provide a better fit to the data than the unadjusted model. 
EQW was associated with a lower risk of nausea compared to all GLP-1 RAs, except 
exenatide 5ug BID (none of these differences were statistically significant). Risk 
of discontinuation due to adverse events was lower for EQW than for dulaglutide 
1.5mg QW, and liraglutide 1.2mg and 1.8mg QD, and higher for EQW than for lixi-
senatide 20ug QD and exenatide 5ug and 10ug BID (none of these differences were 
statistically significant). cOnclusiOns: Evidence suggests that EQW is an effective, 
well-tolerated therapeutic option for the treatment of T2DM in adults inadequately 
controlled on MET alone.
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Objectives: The growing prevalence of T2DM in Europe poses a significant economic 
and healthcare burden, mainly due to diabetes-related complications. Maintaining 
HbA1c below 7% has been shown to reduce the risk of complications in the longer 
term. In the absence of direct evidence comparing sodium glucose co-transporter 
2 (SGLT2) inhibitors, indirect comparisons are needed to inform clinical and policy 
decisions. This analysis assessed the proportion of patients reaching the defined 
HbA1c goal of less than 7% with canagliflozin versus dapagliflozin and empagliflo-
zin added to MET+SU. MethOds: A systematic literature review identified 14 ran-
domised controlled trials, which were used to perform a Bayesian NMA to estimate 
the relative efficacy of canagliflozin added to MET+SU at 26±4 weeks. Relative efficacy 
was evaluated based on odds ratios (ORs) of the proportions of patients reaching 
the HbA1c target and Bayesian pairwise probabilities (P). Interpretation of results 
was based on ORs and P, where P≤ 30% indicated a smaller effect and P≥ 70% a larger 
effect. Results: Canagliflozin 100 mg had similar odds of reaching HbA1c< 7% 
compared to dapagliflozin 10 mg and empagliflozin 25 mg (ORs of 1.12 [P= 60%] and 
0.94 [P= 44%], respectively), and higher odds versus empagliflozin 10 mg (OR of 1.26 
[P= 73%]). Patients treated with canagliflozin 300 mg had higher odds of reaching 
HbA1c< 7% versus dapagliflozin 10 mg and empagliflozin 25 and 10 mg (ORs of 2.03 
[P= 94%], 1.71 [P= 93%], and 2.29 [P= 99%], respectively). cOnclusiOns: This NMA of 
add-on therapies to MET+SU suggests that the odds of achieving HbA1c< 7% at 26 
weeks were at least similar for canagliflozin 100 mg and greater for canagliflozin 300 
mg versus dapagliflozin and empagliflozin.
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Objectives: To assess the relative efficacy of canagliflozin, a sodium glucose 
co-transporter 2 (SGLT2) inhibitor, as add-on to metformin, versus newer anti-
hyperglycaemic agents (AHAs) that were not studied in phase 3 trials, namely 
glucagon-like peptide-1 receptor agonists and other SGLT2 inhibitors (i.e., dapa-
gliflozin and empagliflozin). Data from trials 102 to 104 weeks in length were 
included to compare the longer-term efficacy. MethOds: Bayesian NMAs of 
HbA1c, weight and systolic blood pressure (SBP) change were conducted. Networks 
had treatment- and dose-specific nodes where feasible. As two different meth-
ods to account for missing data were used in the publications (last observation 
carried forward [LOCF] and mixed model repeated measures [MMRM]), two sepa-
rate networks were constructed for each outcome. Interpretation of results was 
based on absolute differences and Bayesian probabilities for treatments to perform 
better than others (P), where P≤ 30% and P≥ 70% indicated a smaller and larger 
effect, respectively. Results: The systematic review identified 11 studies. Seven 
and five studies were included in LOCF and MMRM networks, respectively. In the 
LOCF analysis, canagliflozin 300mg ranked first with greater HbA1c reductions 
than liraglutide 1.2mg/1.8mg and empagliflozin 25mg (D= –0.11%, –0.09%, –0.08%); 
canagliflozin 100mg had similar HbA1c reductions. Both canagliflozin doses had 
higher weight reductions than liraglutide 1.2mg/1.8mg and similar reductions 
versus empagliflozin 25mg. Both canagliflozin doses had greater SBP-lowering 
than liraglutide 1.2mg/1.8mg (D= –1.11 to –2.68mmHg) and a lower effect versus 
empagliflozin 25mg (D= 0.81 to 1.87mmHg). In the MMRM network, canagliflozin 
300 and 100mg had greater and similar HbA1c reductions, respectively, versus 
dapagliflozin. Weight loss was marginally higher for dapagliflozin (D= 0.42 to 
0.59kg). Both canagliflozin doses conferred at least similar SBP-lowering versus 
dapagliflozin. cOnclusiOns: These NMAs suggest that over 2 years, canagliflozin 
offers the opportunity for improved glycaemic control compared with other AHAs, 
with the added benefits of weight loss and BP reduction.
